Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination
- PMID: 34059544
- PMCID: PMC8169472
- DOI: 10.1136/bcr-2021-242220
Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination
Abstract
Immune thrombocytopenia (ITP) has been widely reported as a complication of SARS-CoV-2 infection, but to our knowledge, there have been no reports on the association of the COVID-19 vaccine with thrombocytopenia. Here, we report a case of secondary ITP in a patient who was recently immunised with the messenger RNA COVID-19 vaccine BNT162b2 (Pfizer-BioNTech).
Keywords: COVID-19; immunological products and vaccines.
© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
References
-
- ECDC . Situation updates on COVID-19. European centre for disease prevention and control, European Union. Solna, Sweden, 2020. Available: https://www.ecdc.europa.eu/en/covid-19/situation-updates [Accessed 02 Feb 2021].
-
- Gobierno de México . COVID-19, daily technical report. Mexico's Ministry of health. México, 2021. Available: https://www.gob.mx/cms/uploads/attachment/file/613408/Comunicado_Tecnico... [Accessed 02 Feb 2021].
-
- FDA . Emergency use Authorization (EUA) for emergency use of Pfizer-BioNTech COVID-19 vaccine. U.S. food and drug administration. USA, 2020. Available: https://www.fda.gov/media/144412/download [Accessed 02 Feb 2021].
-
- Mexico Ministry of health . Emergency use Authorization (México) for Pfizer-BioNTech COVID-19 vaccine. México, 2020. Available: https://www.gob.mx/cofepris/articulos/la-cofepris-otorga-autorizacion-pa... [Accessed 02 Feb 2020].
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous